Invivo Theraptc Cm (NVIV) 5.96 $NVIV
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors
BusinessWire - Wed Jun 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christina Morrison to its Board of Directors effective immediately. Most recently, Ms. Morrison served as the Senior Vice President of Finance for Aramark, where she was responsible for treasury, including oversight of over $5 billion of debt, global shared services, which processes certain accounting functions as well as certain human resource functions for over 120,000 employees, and mergers & acquisitions. She joined Aramark in June 2013 as Senior Vice President of Finance.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Featured on CBS Radio Affiliate
BusinessWire - Thu May 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a WBZ NewsRadio 1030 (CBS - Boston) interview with New England Business reporter Jeff Brown. Mr. Brown has been with WBZ NewsRadio since 2012 and is a 30-year veteran of the broadcast industry. The interview aired a number of times on May 23 and May 24 with a total audience reach of nearly a half million listeners.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries Using a Broad Array of Polymeric Implants, Including the Neuro-Spinal Scaffold(TM)
BusinessWire - Wed May 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/694,466, titled "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries". The application covers methods of treatment of compression or contusion spinal cord injuries with a broad array of biodegradable and/or bioabsorbable polymeric implants that includes InVivo's Neuro-Spinal Scaffold(TM), which is currently being studied in the pivotal INSPIRE study. Of note, the allowed claims cover methods of use for a broader spectrum of polymeric compositions than claims in previously granted U.S. Patent No. 9,101,695 issued on August 11, 2015 and U.S. Patent No. 8,858,966 issued on October 14, 2014. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children's Hospital and the Massachusetts Institute of Technology (MIT). A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE Study
BusinessWire - Wed May 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Hospital of the University of Pennsylvania (HUP), a part of the University of Pennsylvania Health System in Philadelphia, PA, has been added as a clinical site for The INSPIRE Study.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Reports 2016 First Quarter Financial Results and Business Update
BusinessWire - Fri May 06, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2016.
NVIV: 5.96 (-0.16)
These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 5.96 (-0.16), OGXI: 1.08 (+0.06), SEED: 1.71 (+0.03), TCS: 4.89 (+0.25)
InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold(TM) in the INSPIRE Study
BusinessWire - Tue Apr 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement.
NVIV: 5.96 (-0.16)
InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications
BusinessWire - Wed Apr 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, is scheduled to present at the Committee Roundtable on Biomedical Engineering Materials and Applications (BEMA) to be held on Monday, April 25, 2016 in Washington, D.C. The topic of the session is "Neuro Devices and Neuro Regeneration".
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces John A. McCarthy, Jr. to Not Stand for Re-election
BusinessWire - Tue Apr 12, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that John A. McCarthy, Jr. has decided not to stand for re-election to the Board of Directors at the Company's 2016 Annual Meeting of the Stockholders. Mr. McCarthy is departing to devote more time to his role as Chief Executive Officer and a director of ZS Genetics, Inc. as well as his other business ventures. Mr. McCarthy will continue to serve as a director of the Company until the expiration of his term at the conclusion of the Company's 2016 Annual Meeting of Stockholders.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces University of Virginia Health System as New Site for INSPIRE Study
BusinessWire - Tue Apr 05, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Virginia (UVA) Health System in Charlottesville, VA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The UVA Health System serves a large geographic area with a population base of approximately 800,000 in central Virginia and receives transfers from the rest of the state.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Featured in Life Science Leader
BusinessWire - Mon Apr 04, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a Life Science Leader article titled "InVivo Therapeutics: Taking on Spinal Cord Injury" as part of The Enterprisers series.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Enrollment of Seventh Patient into The INSPIRE Study
BusinessWire - Thu Mar 24, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a seventh patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Carolinas Medical Center in Charlotte, NC. Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center and a member of the INSPIRE Study Steering Committee, performed the implantation approximately 21 hours after the injury occurred. He and Dr. William Bockenek, Chief Medical Officer at Carolinas Rehabilitation, are Co-Principal Investigators at this site.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Holdings Corp. Closes Exercise of Over-Allotment
BusinessWire - Wed Mar 23, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV), today announced the closing of the exercise of the over-allotment option granted to the underwriters in connection with its previously announced public offering. The underwriters purchased an additional 560,000 shares of InVivo's common stock, bringing the total proceeds of the offering to approximately $32.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants. In connection with the initial closing of the offering on March 18, 2016, InVivo issued 3,733,333 units at a price of $7.50 per unit, each unit consisting of one share of common stock and .50 of a warrant to purchase a share of common stock at an exercise price of $10.00 per share. At the initial closing, the underwriters exercised their over-allotment option to purchase additional warrants to purchase an additional 280,000 shares of common stock. InVivo intends to use the net proceeds from this offering to fund ongoing clinical trials and for general corporate purposes.
NVIV: 5.96 (-0.16)
InVivo Therapeutics to Present at 2016 American Spinal Injury Association Annual Scientific Meeting
BusinessWire - Tue Mar 22, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Lorianne Masuoka, M.D., Chief Medical Officer, is scheduled to present at the 2016 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 14-16, 2016 in Philadelphia, PA. Dr. Masuoka was invited to present along with several other leaders in the field of spinal cord injury clinical research on April 15th at 3:00 PM (EDT) during the symposium titled "Clinical Trials Update for 2016". The symposium, organized by the Spinal Cord Outcomes Partnership Endeavor (SCOPE), is intended to appeal to a wide audience of basic science researchers, clinical researchers, and spinal cord injury clinicians.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Holdings Corp. Announces Pricing of Public Offering of Common Stock and Warrants
BusinessWire - Tue Mar 15, 8:10AM CDT
InVivo Therapeutics Holdings Corp. (NVIV), today announced the pricing of an underwritten public offering of 3,733,333 units at a public offering price of $7.50 per unit. Each unit consists of one share of common stock and .50 of a warrant to purchase a share of common stock at an exercise price of $10.00 per share. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Holdings Corp. Announces Proposed Public Offering
BusinessWire - Mon Mar 14, 3:01PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants to purchase shares of common stock are being offered as units. The shares of common stock and warrants will be immediately separable and will be issued separately. In connection with this offering, InVivo intends to grant the underwriters an option to purchase an additional 15% of the securities sold in the offering. All securities in the offering are being offered by InVivo. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering. Raymond James & Associates, Inc. will act as the sole book-running manager in the offering.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Thomas Jefferson University Hospital as New Site for INSPIRE Study
BusinessWire - Tue Mar 08, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Jefferson University Hospital has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Thomas Jefferson University Hospital, in affiliation with the Magee Rehabilitation Hospital, is designated as one of the nation's 14 Spinal Cord Injury (SCI) Model Systems Centers by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR). James Harrop, M.D., Professor of Neurological Surgery and Co-Director for Adult Reconstructive Spine, has been named Principal Investigator at the site.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Reports Significant Improvement of Fifth Patient Implanted with the Neuro-Spinal Scaffold(TM) in INSPIRE Study
BusinessWire - Mon Mar 07, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced a six-month post-implant update for the fifth patient in The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Reports 2015 Year End Financial Results and Business Update
BusinessWire - Fri Mar 04, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2015.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors
BusinessWire - Wed Jun 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christina Morrison to its Board of Directors effective immediately. Most recently, Ms. Morrison served as the Senior Vice President of Finance for Aramark, where she was responsible for treasury, including oversight of over $5 billion of debt, global shared services, which processes certain accounting functions as well as certain human resource functions for over 120,000 employees, and mergers & acquisitions. She joined Aramark in June 2013 as Senior Vice President of Finance.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Featured on CBS Radio Affiliate
BusinessWire - Thu May 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a WBZ NewsRadio 1030 (CBS - Boston) interview with New England Business reporter Jeff Brown. Mr. Brown has been with WBZ NewsRadio since 2012 and is a 30-year veteran of the broadcast industry. The interview aired a number of times on May 23 and May 24 with a total audience reach of nearly a half million listeners.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries Using a Broad Array of Polymeric Implants, Including the Neuro-Spinal Scaffold(TM)
BusinessWire - Wed May 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/694,466, titled "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries". The application covers methods of treatment of compression or contusion spinal cord injuries with a broad array of biodegradable and/or bioabsorbable polymeric implants that includes InVivo's Neuro-Spinal Scaffold(TM), which is currently being studied in the pivotal INSPIRE study. Of note, the allowed claims cover methods of use for a broader spectrum of polymeric compositions than claims in previously granted U.S. Patent No. 9,101,695 issued on August 11, 2015 and U.S. Patent No. 8,858,966 issued on October 14, 2014. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children's Hospital and the Massachusetts Institute of Technology (MIT). A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE Study
BusinessWire - Wed May 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Hospital of the University of Pennsylvania (HUP), a part of the University of Pennsylvania Health System in Philadelphia, PA, has been added as a clinical site for The INSPIRE Study.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Reports 2016 First Quarter Financial Results and Business Update
BusinessWire - Fri May 06, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2016.
NVIV: 5.96 (-0.16)
These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 5.96 (-0.16), OGXI: 1.08 (+0.06), SEED: 1.71 (+0.03), TCS: 4.89 (+0.25)
InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold(TM) in the INSPIRE Study
BusinessWire - Tue Apr 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement.
NVIV: 5.96 (-0.16)
InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications
BusinessWire - Wed Apr 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, is scheduled to present at the Committee Roundtable on Biomedical Engineering Materials and Applications (BEMA) to be held on Monday, April 25, 2016 in Washington, D.C. The topic of the session is "Neuro Devices and Neuro Regeneration".
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces John A. McCarthy, Jr. to Not Stand for Re-election
BusinessWire - Tue Apr 12, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that John A. McCarthy, Jr. has decided not to stand for re-election to the Board of Directors at the Company's 2016 Annual Meeting of the Stockholders. Mr. McCarthy is departing to devote more time to his role as Chief Executive Officer and a director of ZS Genetics, Inc. as well as his other business ventures. Mr. McCarthy will continue to serve as a director of the Company until the expiration of his term at the conclusion of the Company's 2016 Annual Meeting of Stockholders.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces University of Virginia Health System as New Site for INSPIRE Study
BusinessWire - Tue Apr 05, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Virginia (UVA) Health System in Charlottesville, VA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The UVA Health System serves a large geographic area with a population base of approximately 800,000 in central Virginia and receives transfers from the rest of the state.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Featured in Life Science Leader
BusinessWire - Mon Apr 04, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a Life Science Leader article titled "InVivo Therapeutics: Taking on Spinal Cord Injury" as part of The Enterprisers series.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Enrollment of Seventh Patient into The INSPIRE Study
BusinessWire - Thu Mar 24, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a seventh patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Carolinas Medical Center in Charlotte, NC. Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center and a member of the INSPIRE Study Steering Committee, performed the implantation approximately 21 hours after the injury occurred. He and Dr. William Bockenek, Chief Medical Officer at Carolinas Rehabilitation, are Co-Principal Investigators at this site.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Holdings Corp. Closes Exercise of Over-Allotment
BusinessWire - Wed Mar 23, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV), today announced the closing of the exercise of the over-allotment option granted to the underwriters in connection with its previously announced public offering. The underwriters purchased an additional 560,000 shares of InVivo's common stock, bringing the total proceeds of the offering to approximately $32.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants. In connection with the initial closing of the offering on March 18, 2016, InVivo issued 3,733,333 units at a price of $7.50 per unit, each unit consisting of one share of common stock and .50 of a warrant to purchase a share of common stock at an exercise price of $10.00 per share. At the initial closing, the underwriters exercised their over-allotment option to purchase additional warrants to purchase an additional 280,000 shares of common stock. InVivo intends to use the net proceeds from this offering to fund ongoing clinical trials and for general corporate purposes.
NVIV: 5.96 (-0.16)
InVivo Therapeutics to Present at 2016 American Spinal Injury Association Annual Scientific Meeting
BusinessWire - Tue Mar 22, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Lorianne Masuoka, M.D., Chief Medical Officer, is scheduled to present at the 2016 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 14-16, 2016 in Philadelphia, PA. Dr. Masuoka was invited to present along with several other leaders in the field of spinal cord injury clinical research on April 15th at 3:00 PM (EDT) during the symposium titled "Clinical Trials Update for 2016". The symposium, organized by the Spinal Cord Outcomes Partnership Endeavor (SCOPE), is intended to appeal to a wide audience of basic science researchers, clinical researchers, and spinal cord injury clinicians.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Holdings Corp. Announces Pricing of Public Offering of Common Stock and Warrants
BusinessWire - Tue Mar 15, 8:10AM CDT
InVivo Therapeutics Holdings Corp. (NVIV), today announced the pricing of an underwritten public offering of 3,733,333 units at a public offering price of $7.50 per unit. Each unit consists of one share of common stock and .50 of a warrant to purchase a share of common stock at an exercise price of $10.00 per share. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Holdings Corp. Announces Proposed Public Offering
BusinessWire - Mon Mar 14, 3:01PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants to purchase shares of common stock are being offered as units. The shares of common stock and warrants will be immediately separable and will be issued separately. In connection with this offering, InVivo intends to grant the underwriters an option to purchase an additional 15% of the securities sold in the offering. All securities in the offering are being offered by InVivo. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering. Raymond James & Associates, Inc. will act as the sole book-running manager in the offering.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Announces Thomas Jefferson University Hospital as New Site for INSPIRE Study
BusinessWire - Tue Mar 08, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Jefferson University Hospital has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Thomas Jefferson University Hospital, in affiliation with the Magee Rehabilitation Hospital, is designated as one of the nation's 14 Spinal Cord Injury (SCI) Model Systems Centers by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR). James Harrop, M.D., Professor of Neurological Surgery and Co-Director for Adult Reconstructive Spine, has been named Principal Investigator at the site.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Reports Significant Improvement of Fifth Patient Implanted with the Neuro-Spinal Scaffold(TM) in INSPIRE Study
BusinessWire - Mon Mar 07, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced a six-month post-implant update for the fifth patient in The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.
NVIV: 5.96 (-0.16)
InVivo Therapeutics Reports 2015 Year End Financial Results and Business Update
BusinessWire - Fri Mar 04, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2015.
NVIV: 5.96 (-0.16)
